Abstract Library

#1483 Biomarker and Target Identification in GEP-NET: From in Silico Prediction to Validation on Patient Tissues

Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of tumors. Somatostatin agonist treatment has a key role in the management of GEP-NET. However, the prognosis of these tumors varies between individuals. There is, therefore, a need to identify novel prognostic and predictive biomarkers of therapeutic efficacy, as well as to propose novel therapeutic strategies.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Tourlet S, Gentien D, Bauchet A, Nicolas A, Blachon J,

Keywords: GPCR, miR,

#1467 iFiT: An Integrative Bioinformatics Platform for Biomarker and Target Discovery. A Case Study in Neuroendocrine Tumors

Introduction: iFiT (Ipsen Focused-on-new bIological enTities and biomarkers) is a Bioinformatics platform integrating systems biology functionalities together with semantic & logic-based artificial intelligence within a high-scale computing environment.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Tourlet S

Authors: Tourlet S, Scaerou F, Martin A, Thiagalingam A, Paty I,

Keywords: Targets iFiT,

#624 Identification of New GPCR Targets in NET Cell Lines Using Ligand Screening

Introduction: Although somatostatin analogs constitute an important part of current therapeutic strategies, both hypersecretion and proliferation of NETs cannot be controlled efficiently in many patients. Identifying and dissecting new molecular targets and regulatory pathways may help to improve diagnostic and therapeutic options for NET patients.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Körner J, Schuldt C, Giesecke Y, Du J, Eichhorn I,

Keywords: secretion, receptor, GPCR, target,

#529 Alternative Splicing and Differential Gene Expression in Pancreatic NETs

Introduction: Protein isoforms resulting from differentially spliced mRNA may constitute peculiar drug targets or markers for cancer diagnosis. We here present a new DNA array that allows identification of splice variation and differential expression for 357 G protein-coupled receptors (GPCR) and 11 proteins of the extracellular matrix.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Körner J, Schäfer C, Schulz P, Wiedenmann B, Grötzinger C,

Keywords: pNET,

#357 Alternative Splicing and Differential Gene Expression in Pancreatic NETs

Introduction: Alternative splicing is an important mechanism to increase diversity of the proteome in higher organisms. These protein isoforms can provide as a selective drug target or marker for cancer diagnosis. We present here a new DNA array that allows identification of splice variation and differential expression of 357 G protein-coupled receptors (GPCR) and 11 proteins of the extracellular matrix.

Conference:

Presenting Author:

Authors: Körner J, Wiedenmann B, Grötzinger C,

Keywords: splice variants array,